CLAIMS

Sub 7

1. A pharmaceutical composition for topical administration, including, as the pharmaceutically active component,

at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof

a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.

- 2. A pharmaceutical composition according to Claim 1, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.
- 3. A pharmaceutical composition according to Claim 1, wherein the pharmaceutically active component is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.
- 4. A pharmaceutical composition according to Claim 3, wherein the pharmaceutically active component is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.
- 5. A pharmaceutical composition according to Claim 1, wherein the pharmaceutically active component is minoxidil or a salt thereof.
- 6. A pharmaceutical composition according to Claim 2, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.
- 7. A pharmaceutical composition according to Claim 2, wherein the acid is a

is dear our many bound of the state of the s

10

3

20

mineral or organic acid.

Sw.

8. A pharmaceutical composition according to Claim 7, wherein the acid includes acetic or lactic acid.

Aug 5

- 9. A pharmaceutical composition according to Claim 1, wherein the solvent composition includes water and ethanol in a range of approximately 1:1 to 1:3 by volume.
- 10. A pharmaceutical composition according to Claim 1, wherein the co-solvent includes benzyl alcohol.
- 11. A pharmaceutical composition according to Claim 1, wherein the solvent composition system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent system.
- 12. A pharmaceutical composition according to Claim 1, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the co-solvent system.
- 13. A pharmaceutical composition according to Claim 1, wherein the co-solvent includes an alkylene glycol.
- 14. A pharmaceutical composition according to Claim 13, wherein the alkylene glycol is selected from one or more of the group consisting of glycerol, 1,3-butylene or propylene glycol.
- 15. A pharmaceutical composition according to Claim 1, wherein the acid is present at a level that provides at least 0.01 Normal acid.
- 16. A pharmaceutical composition according to Claim 1, wherein the acid is present in an amount equal to or greater than the amount of the piperidinopyrimidine derivative in Normal amounts.

10 10

15

20

25



17. A pharmaceutical composition according to Claim 1, wherein the solvent system includes water and ethanol in a range of approximately 9:1 to 1:9 by volume.

- 18. A pharmaceutical composition according to Claim 5, wherein the pharmaceutically active component is a minoxidil salt.
- 19. A pharmaceutical composition according to Claim 18, wherein the minoxidil salt is a minoxidil acetate or lactate salt.
- 20. A pharmaceutical composition according to Claim 1, including approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;

approximately 88 to 95% by weight of a solvent composition including approximately 10 to 70% by weight of ethanol, approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glycol.

21. A method for the treatment of hair loss and related indications in humans, which method includes

providing

a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,

at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;

an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt the reof;

a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and

applying topically to the human scalp a therapeutically or prophylactically

Then there t

20

25

30

effective amount of the pharmaceutical composition.

Sub

- 22. A method according to Claim 21, wherein the pharmaceutically active component includes minoxidil or a minoxidil salt.
- 23. A method according to Claim 22, wherein the minoxidil salt is a minoxidil acetate or lactate salt.
- 24. A method according to Claim 21, wherein the pharmaceutical composition includes

approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil salt;

10 ap

5

approximately 88 to 95% by weight of a solvent composition including approximately 10 to 70% by weight of ethanol, approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glysol.

25. A pharmaceutical composition according to Claim 1, substantially as herein before described with reference to any one of the examples.

ins.